|Project Title||Prospective Postmarketing Surveillance of Acute Myocardial Infarction in New Users of Saxagliptin: A Population-Based Study|
Wednesday, November 1, 2017
The cardiovascular safety of saxagliptin, a dipeptidyl-peptidase 4 inhibitor, compared with other antihyperglycemic treatments is not well understood. This article prospectively examined the association between saxagliptin use and acute myocardial infarction (AMI). The authors did not find a higher AMI risk in saxagliptin users compared with users of other selected antihyperglycemic agents during the first 5 years after U.S. Food and Drug Administration approval of the drug.
anti-diabetic agent (ADA)
dipeptidyl peptidase-4 (DPP-4) inhibitor
acute myocardial infarction (AMI)
- Vaccines, Blood & Biologics
- Devices and Radiologic Health